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MicroRNAs have the capacity to coordinately repress multiple target genes and interfere with bio-
logical functions of the cell, such as proliferation and apoptosis. Here we report that miR-136 is
downregulated in human glioma, and that the miRNA promotes apoptosis of glioma cells induced
by chemotherapy. Two anti-apoptotic genes, AEG-1 and Bcl-2, are identiﬁed as targets of miR-136,
and restoration of AEG-1 or Bcl-2 expression suppresses miR-136-enhanced apoptosis. Therefore,
miR-136 might play a tumor-suppressive role in human glioma and thereby might represent a
potential therapeutic strategy.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction pressive miRNA. Of note, ectopic expression of miR-136 was able toGliomas represent the most common primarymalignancy in the
central nervous system [1]. Despite the advances in therapeutic
intervention, the median survival time of patients with high-grade
gliomas is only 15 months [2–4]. Mounting evidence suggests that
progression of gliomas depends on the rate of not only cell prolifer-
ation but also apoptosis. Therefore, understanding the key regula-
tory mechanisms mediating sustained survival and pro-apoptotic
therapy is key to developing novel and effective therapeutic strate-
gies for gliomas.
MicroRNAs (miRNAs), a class of small regulatory RNA mole-
cules, play important roles in tumorigenesis [5]. Recently, miRNA
microarray expression proﬁling showed that miR-136 was promi-
nently overexpressed murine lung cancers [6]. miR-136 is also re-
ported to be markedly upregulated in the Jurkat cell line [7] and
targeted tumor suppressor PTEN [8], suggesting a possible signiﬁ-
cance of miR-136 in cancer development and/or progression. On
the other hand, however, the expression of miR-136 and its biolog-
ical function in gliomas are largely unknown.
Here we report that miR-136 is downregulated in human gli-
oma cells and clinical samples and might function as a tumor-sup-chemical Societies. Published by E
versity, Zhongshan School of
ong 510080, China. Fax: +86sensitize glioma cells to Cisplatin-induced apoptosis. We have also
shown that AEG-1 and Bcl-2, two anti-apoptotic genes, are directly
targeted by miR-136, contributing to the pro-apoptotic effect of
miR-136. Interestingly, as an anti-apoptotic oncoprotein AEG-1
has been previously found to be upregulated in human gliomas
and correlated with the development and progression of the dis-
ease [9]. Moreover, Bcl-2 is also an apoptosis inhibitor and overex-
pressed in a wide variety of cancer types, including gliomas
[10,11].
2. Materials and methods
2.1. Cell lines
Primary normal human astrocytes (NHA) were purchased from
Sciencell Research Laboratories (Carlsbad, CA) and cultured as
manufacturer suggested. Glioma cell lines, including LN340,
LN382T, LN444, LN464, U87MG, U251MG, SNB19 and A172, were
cultured in DMEM supplemented with 10% fetal bovine serum
(FBS) (HyClone, Logan City, Utah).
2.2. Tumor samples from patients
Seven specimens of human primary glioma and three normal
brain tissue specimens were obtained as previously described
[9,12] (also see Supplementary Materials and Methods).lsevier B.V. All rights reserved.
Fig. 1. MiR-136 is down-regulated in gliomas. (A)miR-136 expression in NHA and indicated glioma cell lines. (B)miR-136 expression in normal human brain (N1, N2 and N3)
and glioma (T1–T7) tissue samples. For (A) and (B), error bars represent standard deviation (SD) of 3 independent experiments with similar results. ⁄: P < 0.05.
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Total RNA extraction, reverse transcription, and real time PCR
were performed as described previously [9,12]. Primers are listed
in Supplementary Table 1.
2.4. Plasmids and transfection
The open reading frames (ORFs) of AEG-1 and BCL2 genes were
PCR ampliﬁed from NHA and cloned into the BamHI/EcoRI sites of
pcDNA3.1-basic plasmid. The 30-UTR regions of human AEG-1
(from nt 2870 to nt 3083) and BCL2 (from nt 3731 to nt 3849) were
generated by PCR and cloned into modiﬁed pGL3-control luciferase
reporter plasmid (Promega, Madison, WI). PCR primers are listed in
Supplementary Table 2. PGL3-AEG-1-30UTR-mu and pGL3-BCL2-
30UTR-mu luciferase reporter plasmids were constructed by using
QuikChange Site-Directed Mutagenesis Kit according to the manu-
facturer’s instruction.Fig. 2. Overexpression of miR-136 promotes Cisplatin-induced apoptosis. (A) TUNEL assa
TUNEL-positive cells. ⁄: P < 0.05 relative to NC without Cisplatin; #: P < 0.05 relative t
indicated cells with a-tubulin as loading control.MiR-136 mimic and negative controls were commercially syn-
thesized by RiboBio (Guangzhou, China) according to the following
sequences: 50-ACUCCAUUUGUUUUGAUGAUGGA-30 (miR-136 mi-
mic sense strand), 50-UCCAUCAUCAAAACAAAUGGAGU-30 (miR-
136 mimic anti-sense strand); 50-UUUGUACUACACAAAAGU-
ACUG-30 (negative control miR sense strand), and 50-CAG-
UACUUUUGUGUAGUACAAA-30 (negative control miR anti-sense
strand). Transfection of microRNA mimics or plasmids was per-
formed using the Lipofectamine 2000 reagent (Invitrogen, Carls-
bad, CA) according to the manufacturer’s instruction.
2.5. Western blotting
Western blotting was performed as described previously [13].
The antibodies used include anti-Metadherin (AEG-1) (Invitrogen,
Carlsbad, CA), anti-Bcl-2, anti-cleaved caspase-3, anti-PARP (Cell
Signaling, Danvers, MA, USA), and anti-alpha-tubulin (Sigma, Saint
Louis, MO, USA).ys in two glioma cell lines transfected and treated as indicated. (B) Quantiﬁcation of
o NC with Cisplatin. (C) Immunoblots for cleaved caspase-3 and cleaved PARP in
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TUNEL assay was performed using a commercially available kit
(Promega, Madison, WI) according to the manufacturer’s instruc-
tion as previously described [14].
2.7. Luciferase assay
Dual–Luciferase reporter assays were performed according to
the manufacturer’s instructions (Promega, Madison, WI) as previ-
ously described [9,12].
2.8. Statistical analysis
Data are shown as mean ± SD. Statistical signiﬁcance was deter-
mined by Student’s t test, and P < 0.05 was considered to be signif-
icantly different. The Spearman rank correlation coefﬁcients were
calculated to determine the bivariate correlations between study
variables.
3. Results
3.1. Downregulation of miR-136 in gliomas
We ﬁrst examined the expression levels of miR-136 in NHA and
8 human glioma cell lines. All tested glioma cell lines displayed
dramatically decreased expression of miR-136, as compared withFig. 3. MiR-136 directly regulates AEG-1 and Bcl-2. (A) Upper and lower panels, predicte
human Bcl-2-30 UTR. (B) Immunoblots for endogenous AEG-1 and BCL-1 in indicated
between the 30-UTR of AEG-1 or Bcl-2 and miR-136 in indicated cells. n = 3, ⁄: P < 0.05, #:P
miR-136 and AEG-1 or Bcl-2 in glioma cell lines. Dots represent the relative protein expthat in NHA (Fig. 1A). Downregulation of miR-136 was also found
in clinical samples. In contrast with 3 normal brain tissues, miR-
136 expression in all 7 examined glioma samples was signiﬁcantly
declined (Fig. 1B). To determine whether the differential expres-
sion of miR-136 between normal and tumor was speciﬁc, miR-
16, a microRNA reported to be constitutively expressed in both gli-
oma cells and normal astrocytes [15], was assessed and found, and
as shown in Supplementary Figure, it indeed remained statistically
invariable among normal and malignant cells and tissues. To-
gether, these data suggested that miR-136 was downregulated in
glioma and the downregulation might represent a frequent, clini-
cally relevant molecular alteration in human gliomas.
3.2. miR-136 sensitized glioma cells to Cisplatin induction of apoptosis
To evaluate the effect of miR-136 expression on glioma cells
apoptosis, we transfected LN340 and LN382T with chemically syn-
thesized miR-136 mimic or its correponding negative control (NC),
followed by treatment with Cisplatin at 2.5 lg/ml, a dose approx-
imately half of the peak pharmacological blood level reached dur-
ing chemotherapy [16], or control vehicle (H2O), and subsequent
measurement of cell apoptosis using TUNEL analysis. As shown
in Fig. 2A and B, miR-136 expression slightly promoted apoptotic
rate of glioma cells. Moreover, miR-136 sensitized cells to Cis-
platin-induced death, evidenced by signiﬁcant increase of apopto-
tic rate as compared with those in the NC treatment group in the
presence of Cisplatin (Fig. 2 A and B). Additionally, the pro-apopto-d duplexes formation between miR-136, respectively, and human AEG-1-30 UTR and
cells with a-tubulin as loading control. (C) Reporter gene assay of the interaction
< 0.01. (D) Expression of AEG-1 and Bcl-2 proteins and correlation analysis between
ression levels of AEG-1 and BCL2 normalized to a-tubulin.
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pase-3 and PARP (Fig. 2C).
3.3. miR-136 directly targets AEG-1 and Bcl-2
To understand the molecular mechanisms via which miR-136
potentiate glioma cells to apoptosis, TargetScan search program
was used to predict targets of miR-136, and among the putative
targets predicted, AEG-1 and Bcl-2, two well-known anti-apopto-
tic oncoproteins, were investigated (Fig. 3A). To validate the po-
tential targeting of AEG-1 and Bcl-2 by miR-136, protein
expressions of AEG-1 and Bcl-2 in miR-136 transduced cells
were examined and were found to be suppressed after miR-
136 transfection (Fig. 3B). To identify whether the suppressive
effect of miR-136 on AEG-1 and Bcl-2 expression was direct,
fragments of wild type and mutated 30-UTRs of AEG-1 and Bcl-
2 were fused to luciferase reporter vector. The luciferase activi-
ties were inhibited by overexpressed miR-136 at the presence
of the wild type 30-UTRs, which can be abrogated by mutations
in seed complementary site (Fig. 3, A and C). Furthermore,
AEG-1 and Bcl-2 proteins, respectively, inversely correlated with
miR-136 expression in the cell lines, as shown in Fig. 3D. To-
gether, our results demonstrated that AEG-1 and Bcl-2 were di-
rect targets of miR-136.Fig. 4. Expression of ectopic AEG-1 or Bcl-2 partially abrogates the effect of miR-136. (
TUNEL assays in two glioma cell lines transfected and treated as indicated. (C) Quantiﬁca
with vector, respectively. (D) Immunoblots for cleaved caspase-3 and cleaved PARP in i3.4. Expression of ectopic AEG-1 or Bcl-2 abrogated the pro-apoptotic
effect of miR-136
To explore whether the ability of miR-136 to sensitize cells to
the pro-apoptotic effect of Cisplatin was attributable to suppres-
sion of AEG-1 and Bcl-2, we constructed plasmid expressing
AEG-1 or Bcl-2 ORF and cotransfected it with miR-136 in LN340
and LN382T cells (Fig. 4A). Our result showed that the cotransfec-
tion abrogated, although partially, miR-136-promoted apoptosis
induced by Cisplatin (Fig. 4, B and C). We also observed decreased
levels of cleaved caspase-3 and PARP in cells cotransfected with
miR-136 and AEG-1/Bcl-2, as opposed to those transfected with
miR-136 alone (Fig. 4D). Thus, the observed miR-136-enhanced
apoptosis in glioma cells was mediated, at least in part, by suppres-
sion of AEG-1 and Bcl-2.
4. Discussion
While the roles of miRNAs in cancer have been widely investi-
gated, speciﬁc genes targeted by, and the biological functions of,
many miRNAs, as well as their signiﬁcance in cancer development
and progression, remain incompletely understood. MiR-136, for in-
stance, our knowledge concerning its role in tumorigenesis re-
mains limited. Here, we provide the ﬁrst demonstration thatA) Expression of AEG-1 or Bcl-2 in glioma cells transfected with ORF plasmids. (B)
tion of TUNEL-positive cells. ⁄ and #: P < 0.05 relative to NC with vector and miR-136
ndicated cells with a-tubulin as loading control.
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that such a change might lead to compromised apoptosis of the in-
volved cells due to impeded suppression of two newly identiﬁed
anti-apoptotic targets, namely, AEG-1 and Bcl-2.
From a therapeutic standpoint of view, our data suggest that
restoring miR-136 expression could sensitize glioma cells to Cis-
platin treatment and cause subsequent apoptotic cell death at
doses lower than clinically achievable peak blood concentrations
of Cisplatin, which as a single-agent has little effect on apoptosis
at the dose in the cell model employed in our current study.
In the current study two targets of miR-136, namely, AEG-1 and
Bcl-2, have been investigated for their potential role in mediating
the anti-apoptotic effect of miR-136. Previously, upregulated
expressions of AEG-1 and Bcl-2 has been identiﬁed in clinical as
well as experimental gliomas by us and others [4,9,10,17], in con-
junction with the observed facts that both proteins are anti-apop-
totic, providing a rationale basis for further understanding the
molecular mechanisms via which the expression of these two
important oncogenic proteins is modulated. Notably, the func-
tional association between miR-136 and its target genes (AEG-1
and Bcl-2), together with the low expression of miR-136 in glio-
mas, may represent one of the mechanisms underlying the high
expression of AEG-1 and Bcl-2 in gliomas. It remains to be investi-
gated, however, whether and what other target genes of miR-136
are also involved in the modulation of apoptosis in gliomas.
The identiﬁcation of multi-target property of miR-136 might
help develop new strategies against more than one survival path-
way. Such strategies appear to be essential for a successful therapy
as survival of glioma cells is believed to be supported by multiple
signaling pathways. Whether miR-136 can be developed as a ther-
apeutic approach to the treatment of glioma needs to be addressed
ﬁrst through animal studies.
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